Vertex Pharma falls after Q1 results miss

Shares of Vertex Pharmaceuticals VRTX.O fall 5.04% to $475 premarket

Co posted Q1 revenue of $2.77 billion, missing analyst estimates of $2.85 billion according to data compiled by LSEG

Co raised the low end of its full-year 2025 revenue forecast range to $11.85 billion from $11.75, keeping the higher end at $12 billion

Co saw a revenue decline in Russia where Vertex's intellectual property rights is being violated

Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized copy of co's cystic fibrosis Trikafta in Russia - William Blair

Reports quarterly adj profit of $4.06 per share, below estimates of $4.32

Up to last close, stock down ~24% YTD